Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 9;22(1):15.
doi: 10.1186/s12875-020-01357-w.

Swāsthya, an integrated chronic condition management programme for families of patients with hypertension and diabetes mellitus: a study protocol for a randomised controlled trial

M D Saju  1   2 , Bindiya M Varghese  3 , Lorane Scaria  4   5 , Anuja Maria Benny  4   5 , Shilpa V Yohannan  4   5 , Natania Cheguvera  4   5 , S P Rajeev  6 , Amuthavalli Thiyagarajan Jotheeswaran  7   8
Affiliations

Swāsthya, an integrated chronic condition management programme for families of patients with hypertension and diabetes mellitus: a study protocol for a randomised controlled trial

M D Saju et al. BMC Fam Pract. .

Abstract

Background: Kerala is known as the diabetes mellitus (DM) and hypertension (HTN) capital of the world, thus compelling health professionals to model strategies, addressing their social, behavioural, and cognitive risk factors and eliminating various barriers to management. This paper describes the protocol of our study that aims to examine the effectiveness and sustainability of an integrated care model for the management of chronic conditions and their risk factors through a family-based intervention. The proposed care model targets to modify systems and processes that predispose to chronic conditions by enhancing social cohesion and social networks, preventing lifestyle risks, developing iterative cognitive interventions, and engaging the family into customised treatment adherence strategies navigated by community health social workers (CHSWs).

Methods: A cluster randomised controlled trial (RCT) in selected participants will be conducted involving additional assessments prior to the baseline assessment. The assessment will identify and categorise patients into four risk groups, namely behavioural, social, cognitive, and multiple, based on dominant risks identified. Eligible participants will be randomly allocated (at a ratio of 1:1) into the intervention or control arm. The intervention arm will receive social, behavioural, and cognitive or multiple interventions corresponding to the identified risk groups, whereas the control arm will receive general intervention. Both the groups will be followed up at 6 months and 12 months post baseline to measure outcomes. The primary outcome will be the control of HTN and DM, and secondary outcomes include decreased depression and anxiety and improved functioning, social cohesion, and social network linkages. The sustainability and scalability of this intervention will be assessed through cost effectiveness, acceptability, and user friendliness of the integrated approach by performing a qualitative evaluation.

Discussion: This RCT will inform the potential paradigm shift from a medical model of chronic condition management to a multidimensional, multisystem, and multidisciplinary convergence model navigated by CHSWs. Such a model is not currently considered in the management of chronic conditions in Kerala.

Trial registration: Trial has been prospectively registered on Clinical Trial Registry of India- CTRI/2020/12/029474 on 1st December 2020.

Keywords: Diabetes mellitus; Hypertension; India; Integrated care model; Medical compliance; Study protocol.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Assessment Schedule of Enrolment, Interventions and assessment
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, Burton CM, Evans M. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279–84. doi: 10.2337/dc11-1277. - DOI - PMC - PubMed
    1. Egede LE, Gebregziabher M, Echols C, Lynch CP. Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother. 2014;48(5):562–70. doi: 10.1177/1060028014526362. - DOI - PubMed
    1. WHO. Non communicable diseases. World Health Organization; 2018. Retrieved from https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.
    1. Stringhini S, Bovet P. Socioeconomic status and risk factors for non-communicable diseases in low-income and lower-middle-income countries. Lancet Glob Health. 2017;5(3):e230–e231. doi: 10.1016/S2214-109X(17)30054-2. - DOI - PubMed
    1. Banerjee A. Non communicable diseases in India: challenges and the way forward. J Postgrad Med. 2019;65(1):5–6. doi: 10.4103/jpgm.JPGM_157_18. - DOI - PMC - PubMed

Publication types